Georges Gemayel, Gemini interim president and CEO (Orphazyme)
Another burned-out SPAC biotech raises the white flag as CEO departs, strategic review begins
Five months after Gemini CEO Jason Meyenburg spelled out his survival plan for the little biotech, he’s now out of the picture as the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
